Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | NEU2 | Q9Y3R4 | 3/20 | 0.47 |
| ▸ | NEU4 | Q8WWR8 | 2/20 | 0.47 |
| ▸ | NEU3 | Q9UQ49 | 2/20 | 0.47 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.47 |
| ▸ | SELL | P14151 | 1/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | MAG | P20916 | 2/20 | 0.42 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sialic Acid SCHEMBL15343921 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL8503823 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL22879166 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL16549477 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL23366253 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL24274184 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL22279106 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL21067569 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL22943658 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 | |
| Sialic Acid SCHEMBL13703572 | 1.00 | NANP (0.72) | NANPL3MBTL1NEU2NEU4NEU3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9157105-B2 | Biosynthesis of CMP-legionaminic acid from fructose-6-P, and respective pathway intermediates, using novel GDP-linked precursors | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2015-10-13 | — | — | US | disclosed |
| US-8754192-B2 | Compositions comprising homogeneously glycosylated erythropoietin | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-06-17 | — | — | US | disclosed |
| US-8053410-B2 | Pegylated factor VII glycoforms | NOVO NORDISK HEALTH CARE A/G (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
| US-20090048440-A1 | Nucleotide Sugar Purification Using Membranes | NEOSE TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080039373-A1 | Pegylated Factor VII Glycoforms | NOVO NORDISK A/S (DK) | 2008-02-14 | — | — | US | disclosed |
| WO-2007120614-A2 | HOMOGENEOUS ERYTHROPOIETIN AND OTHER PEPTIDES AND PROTEINS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048440-A1 | Nucleotide Sugar Purification Using Membranes | SLC35B2, SLC35A1, GALNT1 | NANP 35/4885L3MBTL1 2282/4885NEU2 24/4885 |
| US-20100081786-A1 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation | EPOR, LIFR, LNPEP | NANP 3436/4885L3MBTL1 313/4885NEU2 2151/4885 |
| US-20080039373-A1 | Pegylated Factor VII Glycoforms | F7, F13B, F5 | NANP 247/4885L3MBTL1 1805/4885NEU2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.